In this review, we provide an overview of how GPCR signaling and EV trafficking cooperate to support tumor survival and progression, and propose the potential for targeting GPCRs to modulate cancer-associated EVs as a therapeutic strategy. The gene discussed is LPAR3; the disease is cancer.